| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CPT7; CYP17; P450C17; S17AH; CYP17A1;;Cytochrome P450 17A1 |
| WB Predicted band size | Calculated MW: 57 kDa ; Observed MW: 50 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human Cytochrome P450 17A1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于Cytochrome P450 17A1(CYP17A1)抗体的参考文献示例，包含文献名称、作者及简要摘要内容：
---
1. **文献名称**：*Molecular cloning and expression of human cytochrome P450 17A1: Immunochemical characterization and tissue distribution*
**作者**：Chung BC, et al.
**摘要**：该研究通过分子克隆技术鉴定了人CYP17A1的基因序列，并制备了特异性抗体。通过免疫印迹(Western blot)和免疫组化验证抗体在肾上腺、性腺等组织中的表达，证实了抗体的特异性与敏感性。
2. **文献名称**：*CYP17A1 expression in prostate cancer: Immunohistochemical analysis and clinical correlation*
**作者**：Yamamoto Y, et al.
**摘要**：研究利用CYP17A1特异性抗体对前列腺癌组织进行免疫组化分析，发现其表达水平与肿瘤侵袭性相关，提示CYP17A1可能作为潜在治疗靶点。抗体验证包括阴性对照和竞争性抑制实验。
3. **文献名称**：*Role of cytochrome P450 17A1 in steroidogenesis: Insights from antibody-mediated inhibition studies*
**作者**：Pandey AV, et al.
**摘要**：通过抗CYP17A1抗体阻断酶活性，探究其在类固醇激素合成中的功能。研究采用免疫沉淀和酶活性检测，证实抗体可有效抑制17α-羟化酶和17.20-裂解酶活性，为疾病模型研究提供工具。
4. **文献名称**：*Tissue-specific regulation of CYP17A1: Evidence from genetic and antibody-based profiling*
**作者**：Sherva R, et al.
**摘要**：结合基因多态性数据与抗体检测的蛋白表达(Western blot和免疫荧光)，揭示了CYP17A1在不同组织中的调控差异，强调了抗体在解析酶表达模式中的关键作用。
---
这些文献涵盖了抗体的开发、验证及在疾病机制研究中的应用，适用于实验设计或论文写作中的方法学参考。
Cytochrome P450 17A1 (CYP17A1) is a critical enzyme in steroidogenesis, primarily expressed in the adrenal glands and gonads. It catalyzes two key reactions: the 17α-hydroxylation of pregnenolone/progesterone to form precursors for glucocorticoids and the 17.20-lyase activity required for androgen synthesis. Dysregulation of CYP17A1 is linked to endocrine disorders, such as congenital adrenal hyperplasia, polycystic ovary syndrome (PCOS), and hormone-sensitive cancers like prostate cancer. Antibodies targeting CYP17A1 are essential tools for studying its expression, localization, and function in both normal physiology and disease contexts.
CYP17A1 antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect protein levels in tissues, cell lysates, or biological fluids. These antibodies help researchers investigate tissue-specific steroidogenic activity, evaluate therapeutic responses to CYP17A1 inhibitors (e.g., abiraterone in prostate cancer), or explore genetic mutations affecting enzyme activity. Monoclonal antibodies offer high specificity, while polyclonal versions may detect multiple epitopes, enhancing sensitivity. Validation via knockout controls or enzymatic assays is crucial to confirm antibody reliability.
Clinically, CYP17A1 antibodies may aid in diagnosing adrenal or gonadal tumors with aberrant steroid production. Their role in elucidating molecular pathways also supports drug development targeting steroid hormone-dependent conditions.
×
